Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 21 versus TRI LO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 21 versus TRI LO LINYAH.
DEMULEN 1/35-21 vs TRI-LO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
None Documented
None Documented
Ethinyl estradiol: 13±3 hours (terminal); norethindrone: 8±3 hours. Steady-state achieved after ~5 days.
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Renal (primarily as glucuronide and sulfate conjugates): ~60%; fecal: ~40%
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive